These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36166004)

  • 1. A Novel B7-H6-Targeted IgG-Like T Cell-Engaging Antibody for the Treatment of Gastrointestinal Tumors.
    Zhang W; Auguste A; Liao X; Walterskirchen C; Bauer K; Lin YH; Yang L; Sayedian F; Fabits M; Bergmann M; Binder C; Corrales L; Vogt AB; Hudson LJ; Barnes MP; Bisht A; Giragossian C; Voynov V; Adam PJ; Hipp S
    Clin Cancer Res; 2022 Dec; 28(23):5190-5201. PubMed ID: 36166004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
    Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
    Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
    Zhang T; Wu MR; Sentman CL
    J Immunol; 2012 Sep; 189(5):2290-9. PubMed ID: 22851709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
    Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
    Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical significance of costimulatory molecule B7-H3 expression on CD3(+) T cells in colorectal carcinoma.
    Mao Y; Sun J; Wang WP; Zhang XG; Hua D
    Chin Med J (Engl); 2013 Aug; 126(16):3035-8. PubMed ID: 23981607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgG-based B7-H3xCD3 bispecific antibody for treatment of pancreatic, hepatic and gastric cancer.
    Lutz MS; Zekri L; Weßling L; Berchtold S; Heitmann JS; Lauer UM; Jung G; Salih HR
    Front Immunol; 2023; 14():1163136. PubMed ID: 37122707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
    Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
    Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel GUCY2C-CD3 T-Cell Engaging Bispecific Construct (PF-07062119) for the Treatment of Gastrointestinal Cancers.
    Mathur D; Root AR; Bugaj-Gaweda B; Bisulco S; Tan X; Fang W; Kearney JC; Lucas J; Guffroy M; Golas J; Rohde CM; Stevens C; Kamperschroer C; Kelleher K; Lawrence-Henderson RF; Upeslacis E; Yao J; Narula J; LaVallie ER; Fernandez DR; Buetow BS; Rosfjord E; Bloom L; King LE; Tchistiakova L; Nguyen A; Sapra P
    Clin Cancer Res; 2020 May; 26(9):2188-2202. PubMed ID: 31996389
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An optimized IgG-based B7-H3xCD3 bispecific antibody for treatment of gastrointestinal cancers.
    Zekri L; Lutz M; Prakash N; Manz T; Klimovich B; Mueller S; Hoerner S; Hagelstein I; Engel M; Chashchina A; Pfluegler M; Heitmann JS; Jung G; Salih HR
    Mol Ther; 2023 Apr; 31(4):1033-1045. PubMed ID: 36793213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
    Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
    J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells.
    Sun X; Zhao J; Ma L; Sun X; Ge J; Yu Y; Ma J; Zhang M
    Invest New Drugs; 2021 Feb; 39(1):24-33. PubMed ID: 32770284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H6 expression correlates with cancer progression and patient's survival in human ovarian cancer.
    Zhou Y; Xu Y; Chen L; Xu B; Wu C; Jiang J
    Int J Clin Exp Pathol; 2015; 8(8):9428-33. PubMed ID: 26464699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The B7 Family Member B7-H6: a New Bane of Tumor.
    Chen Y; Mo J; Jia X; He Y
    Pathol Oncol Res; 2018 Oct; 24(4):717-721. PubMed ID: 29086181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H6 protein expression has no prognostic significance in human gastric carcinoma.
    Chen XJ; Shen J; Zhang GB; Chen WC
    Pathol Oncol Res; 2014 Jan; 20(1):203-7. PubMed ID: 24242703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 17. Development of T-cell engagers selective for cells co-expressing two antigens.
    Dicara DM; Bhakta S; Go MA; Ziai J; Firestein R; Forrest B; Gu C; Leong SR; Lee G; Yu SF; Polson AG; Agard NJ
    MAbs; 2022; 14(1):2115213. PubMed ID: 36206404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B7-H6 expression is induced by lipopolysaccharide and facilitates cancer invasion and metastasis in human gliomas.
    Che F; Xie X; Wang L; Su Q; Jia F; Ye Y; Zang L; Wang J; Li H; Quan Y; You C; Yin J; Wang Z; Li G; Du Y; Wang L
    Int Immunopharmacol; 2018 Jun; 59():318-327. PubMed ID: 29679856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multifunctional NK Cell-Engaging Antibodies Targeting EGFR and NKp30 Elicit Efficient Tumor Cell Killing and Proinflammatory Cytokine Release.
    Klausz K; Pekar L; Boje AS; Gehlert CL; Krohn S; Gupta T; Xiao Y; Krah S; Zaynagetdinov R; Lipinski B; Toleikis L; Poetzsch S; Rabinovich B; Peipp M; Zielonka S
    J Immunol; 2022 Nov; 209(9):1724-1735. PubMed ID: 36104113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity.
    Peipp M; Derer S; Lohse S; Staudinger M; Klausz K; Valerius T; Gramatzki M; Kellner C
    Oncotarget; 2015 Oct; 6(31):32075-88. PubMed ID: 26392331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.